What is Torigen Pharmaceuticals?
Torigen Pharmaceuticals Inc. is dedicated to providing accessible companion animal immuno-oncology solutions. The company's proprietary technology involves using a portion of the pet's tumor to create a personalized cancer vaccine. With a foundation built on over a decade of pre-clinical research, Torigen's team is committed to advancing veterinary cancer biologics that enable the animal's immune system to identify foreign tumor-associated antigens and reverse immune senescence, offering new hope for pets battling cancer.
How much funding has Torigen Pharmaceuticals raised?
Torigen Pharmaceuticals has raised a total of $16.1M across 2 funding rounds:
Series A
$3.1M
Series A
$13M
Series A (2019): $3.1M with participation from Connecticut Innovations
Series A (2022): $13M led by Connecticut Innovations, Emerald Development Managers, and Gaingels
Key Investors in Torigen Pharmaceuticals
Connecticut Innovations
Connecticut Innovations is the state's strategic venture capital arm, providing crucial equity and debt financing, alongside strategic guidance, to help innovative companies scale, with a particular focus on biosciences.
Emerald Development Managers
Emerald Development Managers is a venture capital firm specializing in life sciences and other technology sectors, investing in scientific teams to solve real-world problems and providing capital and expertise for growth.
Gaingels
Gaingels is a leading investment syndicate supporting the LGBTQ community and allies, investing in high-growth companies across various sectors with a commitment to building inclusive teams.
What's next for Torigen Pharmaceuticals?
The substantial capital infusion, particularly the recent strategic investment, positions Torigen Pharmaceuticals for a significant scaling phase. This backing will likely fuel further research and development, expand clinical trials, and bolster manufacturing capabilities. The company's focus on personalized immuno-oncology for companion animals addresses a growing need in the veterinary market, suggesting a trajectory towards broader market penetration and potential partnerships within the animal health sector. The strategic nature of the recent financing indicates confidence from investors in Torigen's long-term vision and its potential to disrupt the veterinary oncology landscape.
See full Torigen Pharmaceuticals company page
